Danish company prepares to take the psoriasis market by storm – seeks FDA approval

The privately-owned company MC2 Therapeutics will launch their newly developed psoriasis treatment to the American market next year, if all goes well. The company’s product has beaten a Leo Pharma alternative when directly compared in clinical trials, and the FDA will now decide whether to approve the treatment.
"We have peace of mind, because it feels like we are doing the right things. We are constantly building up our case," says Jesper J. Lange, Administrative Drector for MC2 Therapeutics. | Photo: MC2 Therapeutics / PR
"We have peace of mind, because it feels like we are doing the right things. We are constantly building up our case," says Jesper J. Lange, Administrative Drector for MC2 Therapeutics. | Photo: MC2 Therapeutics / PR

MC2 Therapeutics, which is based in Hørsholm, has quietly developed a product that could have a significant impact on the American market for psoriasis treatment.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading